Caris Life Sciences, Inc. $CAI Shares Newly Purchased by Brighton Jones LLC

Brighton Jones LLC bought a new position in shares of Caris Life Sciences, Inc. (NASDAQ:CAI) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 37,894 shares of the company’s stock, valued at approximately $1,161,000.

Several other hedge funds have also recently bought and sold shares of the business. Kestra Advisory Services LLC lifted its position in Caris Life Sciences by 2.5% during the third quarter. Kestra Advisory Services LLC now owns 28,801 shares of the company’s stock valued at $882,000 after buying an additional 711 shares in the last quarter. GAMMA Investing LLC grew its stake in Caris Life Sciences by 133.0% during the third quarter. GAMMA Investing LLC now owns 1,263 shares of the company’s stock worth $39,000 after buying an additional 721 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Caris Life Sciences by 839.4% in the first quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock worth $29,000 after acquiring an additional 1,469 shares in the last quarter. Fifth Third Bancorp acquired a new stake in shares of Caris Life Sciences in the first quarter worth $31,000. Finally, Root Financial Partners LLC acquired a new stake in shares of Caris Life Sciences in the third quarter worth $60,000.

Analyst Ratings Changes

A number of equities analysts have recently commented on CAI shares. Weiss Ratings upgraded shares of Caris Life Sciences from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday. BTIG Research reaffirmed a “buy” rating and set a $38.00 price target on shares of Caris Life Sciences in a research report on Thursday, November 5th. Piper Sandler increased their price target on Caris Life Sciences from $22.00 to $25.00 and gave the company a “neutral” rating in a report on Tuesday. Citigroup raised their price objective on Caris Life Sciences from $28.00 to $36.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Finally, JPMorgan Chase & Co. boosted their price objective on Caris Life Sciences from $25.00 to $35.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. Eight analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.18.

Insiders Place Their Bets

In other Caris Life Sciences news, President David Spetzler sold 478,000 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $24.86, for a total value of $11,883,080.00. Following the completion of the transaction, the president directly owned 1,052,083 shares of the company’s stock, valued at $26,154,783.38. This represents a 31.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Brian Brille sold 400,000 shares of the company’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $30.33, for a total transaction of $12,132,000.00. Following the completion of the transaction, the insider directly owned 230,303 shares of the company’s stock, valued at approximately $6,985,089.99. The trade was a 63.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,004,712 shares of company stock worth $27,205,419 in the last quarter. 50.00% of the stock is owned by corporate insiders.

Caris Life Sciences Trading Up 0.2%

CAI opened at $24.49 on Thursday. The firm’s 50 day moving average is $29.45 and its 200-day moving average is $21.73. Caris Life Sciences, Inc. has a 52-week low of $14.19 and a 52-week high of $36.50. The company has a quick ratio of 5.84, a current ratio of 6.71 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $7.02 billion, a P/E ratio of 74.03, a P/E/G ratio of 7.77 and a beta of 0.71.

Caris Life Sciences (NASDAQ:CAI) last announced its earnings results on Wednesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.02. The business had revenue of $275.36 million during the quarter. Caris Life Sciences had a net margin of 9.16% and a return on equity of 16.00%. Caris Life Sciences’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.08 earnings per share. Analysts expect that Caris Life Sciences, Inc. will post 0.11 EPS for the current fiscal year.

Caris Life Sciences Company Profile

Caris Life Sciences is a precision medicine company that develops molecular profiling and artificial intelligence technologies to support cancer diagnosis and treatment decisions. Its services analyze the biological characteristics of a patient’s tumor to help physicians identify information that may guide care. The company’s offerings include tumor profiling based on DNA and RNA analysis, as well as blood-based testing. Caris also provides molecular data and research services to biopharmaceutical companies to support drug development and the study of cancer.